- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Immix Biopharma stock price target raised to $12 from $8 at H.C. Wainwright | 1 | Investing.com | ||
| Mi | Immix Biopharma closes $93.7 million public offering | 3 | Investing.com | ||
| IMMIX BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 09.12. | Immix Biopharma, Inc.: Immix Biopharma Announces Closing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | 2 | GlobeNewswire (USA) | ||
| 08.12. | Immix Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 08.12. | Immix Biopharma prices $100M equity raise via common stock and warrant offering | 3 | Seeking Alpha | ||
| 08.12. | Immix Biopharma prices $100 million public offering to fund AL amyloidosis drug | 2 | Investing.com | ||
| 08.12. | Immix Biopharma reports 75% complete response rate for NXC-201 | 1 | Investing.com | ||
| 08.12. | Immix Biopharma, Inc.: Immix Biopharma Announces Pricing of Upsized $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants | 99 | GlobeNewswire (Europe) | LOS ANGELES, CA, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a global leader in relapsed/refractory AL Amyloidosis, today announced the... ► Artikel lesen | |
| 08.12. | Immix Biopharma, Inc.: At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis | 71 | GlobeNewswire (Europe) | - NXC-201 demonstrated a complete response (CR) rate of 75% (15/20) (at s/u IFE(-) level) by independent review committee - - In four out of five pending patients, MRD negativity in bone marrow predicts... ► Artikel lesen | |
| 26.11. | Immix Biopharma reicht aktualisierte Prüferzustimmungen für SEC-Registrierungserklärung ein | 3 | Investing.com Deutsch | ||
| 26.11. | Immix Biopharma, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Immix Biopharma appoints commercial leader to head NXC-201 launch | 3 | Investing.com | ||
| 12.11. | Immix Biopharma appoints Michael Grabow as chief commercial officer to drive NXC-201 launch | 1 | Seeking Alpha | ||
| 12.11. | Immix Biopharma beruft Commercial-Leiter für Markteinführung von NXC-201 | 1 | Investing.com Deutsch | ||
| 12.11. | Immix Biopharma, Inc.: Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch | 271 | GlobeNewswire (Europe) |
- Former Chimerix (CMRX, acquired by Jazz for $935 million) Senior Commercial Leader Michael Grabow led Go-To-Market Strategy and Launch for rare disease therapeutic MODEYSO® - - Rare disease commercial... ► Artikel lesen | |
| 07.11. | Immix Biopharma, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 03.11. | Immix Biopharma to present NXC-201 trial data for AL amyloidosis at ASH | 2 | Investing.com | ||
| 03.11. | Immix Biopharma, Inc.: Immix Biopharma's NXC-201 NEXICART-2 Clinical Trial Results Selected for Oral Presentation at ASH 2025 | 179 | GlobeNewswire (Europe) | - Oral presentation Sunday, December 7, at ASH 2025 - LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory... ► Artikel lesen | |
| 06.10. | Immix Biopharma, Inc.: Immix Biopharma to Present Abstract at the upcoming ASH 2025 Annual Meeting | 2 | GlobeNewswire (USA) | ||
| 30.09. | Artificial Intelligence Technology Solutions, Inc.: AITX's RAD and Immix Deepen Partnership with Feature-Rich Technology Integration to Boost Operator Efficiency and Accelerate AI Adoption | 413 | Newsfile | Detroit, Michigan--(Newsfile Corp. - September 30, 2025) - Immix®, the global provider of commercial central station and remote SOC software, and Robotic Assistance Devices, Inc. (RAD), a wholly owned... ► Artikel lesen |
1 2 3 Weiter >>
50 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,30 | +0,63 % | Rheinmetall Aktie: Sehr spannend! - BioNTech, Evotec, Klöckner, PNE und Stabilus im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EVOTEC | 5,190 | 0,00 % | Eilmeldung am Abend: EVOTEC SE rutscht brutal ab! | ||
| BB BIOTECH | 48,750 | 0,00 % | Jade Biosciences secures $45 million in private placement from BB Biotech | ||
| QIAGEN | 38,335 | 0,00 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| CUREVAC | 4,182 | -2,24 % | EILMELDUNG: Curevac-Aktie verliert deutlich - bricht jetzt das Vertrauen weg? | ||
| MODERNA | 25,400 | -0,29 % | Moderna, Inc.: EMA Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Authorization of Moderna's mNEXSPIKE | mNEXSPIKE is Moderna's third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and mRESVIA (Respiratory Syncytial Virus Vaccine)mNEXSPIKE will be available in the... ► Artikel lesen | |
| VALNEVA | 3,704 | -0,27 % | Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ | IXCHIQ- was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups... ► Artikel lesen | |
| AMGEN | 276,75 | -0,04 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| EPIGENOMICS | 0,900 | +1,12 % | PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 5,608 | +0,07 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| STRYKER | 299,40 | 0,00 % | Medizintechnik-Anbieter Stryker hebt erneut Dividende an | ||
| BIOGEN | 148,65 | -0,57 % | Lululemon, Biogen to exit Nasdaq 100 with Alnylam, Seagate among additions | ||
| ILLUMINA | 114,32 | -0,40 % | MyOme, Inc: Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually | Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 48,000 | +0,42 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| NANOREPRO | 1,505 | -2,59 % | EQS-News: NanoRepro AG: Aufsichtsrätin kündigt Amtsniederlegung an | EQS-News: NanoRepro AG
/ Schlagwort(e): Personalie
NanoRepro AG: Aufsichtsrätin kündigt Amtsniederlegung an
09.12.2025 / 18:50 CET/CEST
Für den Inhalt der Mitteilung... ► Artikel lesen |
IMMIX BIOPHARMA INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMIX BIOPHARMA INC finden Sie auf Wallstreet Online.